0
Lung Cancer: Lung Cancer II |

Impact of Angiotensin I-Converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Progression-Free Survival and Overall Survival in Patients With Non-small Cell Lung Cancer FREE TO VIEW

Yun Feng, PhD
Author and Funding Information

Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A310. doi:10.1016/j.chest.2016.02.323
Text Size: A A A
Published online

SESSION TITLE: Lung Cancer II

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: It has been shown that angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) can decrease tumor growth and tumor-associated angiogenesis and inhibit metastasis. In approximately 30% of patients with advanced non-small-cell lung cancer (NSCLC) in East Asia and in 10-15% of patients from Western countries, epidermal growth factor receptor (EGFR) mutations are found.

METHODS: We retrospectively identified 228 patients with histologically confirmed advanced NSCLC and 73 patients with early stage disease, including 105 patients taking antihypertensive drugs. There were 112 patients who received treatment with EGFR tyrosine kinase inhibitors (TKI).

RESULTS: Among all of the patients, there was a significant difference in the progression-free survival (PFS1) of first chemotherapy in the ACEI/ARB group compared with the other patients. Among the patients treated with TKI, there was a significant difference in PFS but not in OS in the ACEI/ARB group compared with the non-ACEI/ARB group. For the patients with advanced NSCLC, there was a significant difference in PFS1 in the ACEI/ARB group compared with the non-ACEI/ARB group.

CONCLUSIONS: ACEI/ARB in combination with standard chemotherapy, including TKI, had positive effects on PFS or OS, regardless of whether the lung cancer was in the early or advanced stage.

CLINICAL IMPLICATIONS: ACEI/ARB in combination with standard chemotherapy, including TKI, had positive effects on PFS or OS, regardless of whether the lung cancer was in the early or advanced stage.

DISCLOSURE: The following authors have nothing to disclose: Yun Feng

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543